Review



msc1094308  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    MedChemExpress msc1094308
    SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, <t>MSC1094308,</t> and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.
    Msc1094308, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 398 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/msc1094308/product/MedChemExpress
    Average 99 stars, based on 398 article reviews
    msc1094308 - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Salvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization"

    Article Title: Salvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization

    Journal: Current Issues in Molecular Biology

    doi: 10.3390/cimb47080598

    SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.
    Figure Legend Snippet: SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.

    Techniques Used: Western Blot, Expressing, Quantitative RT-PCR, Activity Assay, Enzyme-linked Immunosorbent Assay, Griess Assay



    Similar Products

    msc1094308  (MedChemExpress)
    99
    MedChemExpress msc1094308
    SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, <t>MSC1094308,</t> and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.
    Msc1094308, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/msc1094308/product/MedChemExpress
    Average 99 stars, based on 1 article reviews
    msc1094308 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.

    Journal: Current Issues in Molecular Biology

    Article Title: Salvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization

    doi: 10.3390/cimb47080598

    Figure Lengend Snippet: SAL B reduced glycolysis by upregulating MIG1. ( A , B ) Western blot analysis to detect the expression of MIG1 in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( C ) qRT-PCR analysis of Mig1 mRNA in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( D , E ) ATP and NAD + /NADH secretions were determined by Colorimetric method and WST-8 assay, respectively, in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( F ) Lactate secretions were determined by Colorimetric method assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( G , H ) The enzyme activity levels of HK and LDHA were measured in the cell lysate after treatment with LPS or NT and SAL B therapy for 24 h. ( I – K ) Western blot analysis to detect the expression of HK and LDHA in the cell lysate after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( L – N ) IL-1β, IL-6, and TNF-α secretions were determined by ELISA, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. ( O ) NO secretions were determined by Griess assay, respectively, in the cell supernatant after treatment with LPS or NT, MSC1094308, and SAL B therapy for 24 h. Data are presented as means ± SEM. ( n = 3). * p < 0.05, ** p < 0.01. Data are representative of three independent experiments with similar results.

    Article Snippet: 2-deoxy-D-glucose (2-DG) (HY-13966) and msc1094308 (HY-123872) was obtained from MedChemExpress.

    Techniques: Western Blot, Expressing, Quantitative RT-PCR, Activity Assay, Enzyme-linked Immunosorbent Assay, Griess Assay